PRENETICS GLOBAL LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.22 USD | +5.07% |
|
+7.61% | +5.25% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2023 | 2.17Cr 181.52Cr | Sales 2024 * | 3.52Cr 293.87Cr | Capitalization | 7.23Cr 603.82Cr |
|---|---|---|---|---|---|
| Net income 2023 | -6.2Cr -517.61Cr | Net income 2024 * | -4.7Cr -392.38Cr | EV / Sales 2023 | 3.27 x |
| Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 2.05 x |
| P/E ratio 2023 |
-1.06
x | P/E ratio 2024 * |
-1.65
x | Employees | 400 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 78.82% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +5.07% | ||
| 1 week | +7.61% | ||
| Current month | +23.17% | ||
| 1 month | +78.22% | ||
| 3 months | +29.45% | ||
| 6 months | +15.19% | ||
| Current year | +5.25% |
1 week
5.06
6.22
1 month
2.857.84
Current year
2.857.84
1 year
2.8515.00
3 years
2.85131.25
5 years
2.85131.25
10 years
2.85131.25
| Managers | Title | Age | Since |
|---|---|---|---|
Chi Hung Tzang
FOU | Founder | 50 | 01/14/01 |
Sheng Wu Yeung
CEO | Chief Executive Officer | 45 | 01/14/01 |
Hoi Chun Lo
DFI | Director of Finance/CFO | 39 | 01/18/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wing Kwan Chiu
BRD | Director/Board Member | 44 | 18/22/18 |
Zhan Feng Cui
BRD | Director/Board Member | 62 | 01/21/01 |
Sheng Wu Yeung
CEO | Chief Executive Officer | 45 | 01/14/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/24/13 | 6.22 | +5.07% | 21,738 |
| 10/24/10 | 5.92 | +10.04% | 16,900 |
| 09/24/09 | 5.38 | +4.06% | 4,138 |
| 08/24/08 | 5.17 | -6.17% | 17,703 |
| 07/24/07 | 5.51 | -4.67% | 15,766 |
Delayed Quote Nasdaq, May 14, 2024 at 02:00 am IST
More quotes
Prenetics Global Ltd is a company mainly engaged in the diagnostics and genetic testing business. The Company operates its business through two segments. The Diagnostics segment is engaged in the provision of COVID-19 testing services and operation testing laboratories. The Segment is also engaged in the development of health monitoring systems. The Prevention segment is engaged in the provision of genetics testing services to individuals and corporate entities.
Calendar
03/06/2024
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
5.92
USD
Average target price
9
USD
Spread / Average Target
+52.03%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +5.25% | 7.23Cr | |
| -24.86% | 987.42Cr | |
| -11.28% | 273.74Cr | |
| -12.92% | 223.97Cr | |
| -18.21% | 163.37Cr | |
| +60.76% | 138.94Cr | |
| +24.83% | 77Cr | |
| -4.59% | 76Cr | |
| -22.45% | 52Cr | |
| -0.60% | 31Cr |
- Stock Market
- Equities
- PRE Stock